- โTime in range improved from 69% to nearly 77% after 12 weeks in auto mode
- โLow blood sugar episodes decreased and no severe hypoglycemia or DKA occurred
- โPatients with HbA1c above 8% saw the greatest improvements, gaining over 20 percentage points in time in range
| Journal | Diabetes, obesity & metabolism |
| Year | 2026 |
| Authors | Shen, Zeng, Li |
| PMID | 41190360 |
What Was Studied and Why It Matters
Managing type 1 diabetes (T1D) requires constant attention to blood sugar levels โ a burden that falls heavily on both patients and caregivers. Researchers in China wanted to know whether a hybrid closed-loop (HCL) insulin pump system could safely and effectively improve blood sugar control in adolescents and adults with T1D. These "smart" pump systems automatically adjust insulin delivery based on real-time readings from a continuous glucose monitor (CGM), reducing the need for constant manual calculations.
The study followed 126 participants โ 22 teenagers and 104 adults โ over 12 weeks using the Equilยฎ S HCL pump paired with a calibration-free CGM sensor. The results were published in Diabetes, Obesity & Metabolism in 2026.
What the Researchers Found
After 12 weeks with the pump running in automatic mode, participants saw meaningful improvements across every key blood sugar measurement:
- Time in Range (TIR) increased from 69% to nearly 77% โ meaning blood sugar spent significantly more time in the healthy 70โ180 mg/dL zone each day.
- Low blood sugar episodes dropped โ time below 70 mg/dL fell from 3.92% to 2.73%.
- Average sensor glucose decreased from 151 mg/dL to 144 mg/dL.
- Blood sugar swings became less extreme, with both the standard deviation and variability scores improving significantly.
- The share of participants meeting the full set of recommended blood sugar targets more than doubled, from 26% to 57%.
The biggest gains were seen in participants who started the study with an HbA1c above 8.0% โ a group typically considered to have poorer baseline control. Their time in range improved by an average of more than 20 percentage points.
Was It Safe?
Yes. Across the entire 12-week study, there were zero cases of severe low blood sugar, diabetic ketoacidosis (DKA), or serious adverse events. This is an important finding, especially for families of teenagers with T1D who worry about overnight lows or dangerous spikes going unnoticed.
What This Means for Real Patients
For people living with type 1 diabetes, this research reinforces that hybrid closed-loop technology isn't just a convenience โ it's a clinically meaningful tool. Spending more time in range is linked to lower risks of long-term complications like kidney disease, nerve damage, and vision problems.
If you or your child uses an insulin pump and CGM, talk to your endocrinologist about whether an HCL system might be a good fit. Staying stocked with reliable CGM sensors and pump supplies is essential to getting the most from this technology โ MDS Diabetes carries a wide range of CGM supplies and insulin pump accessories to keep your therapy running smoothly.
Bottom Line
A 12-week trial of a hybrid closed-loop insulin pump in China showed that smart insulin delivery significantly improved time in range, reduced dangerous blood sugar swings, and lowered average glucose levels โ all without any serious safety incidents. Patients who started with the poorest control benefited the most, making this technology a compelling option for those struggling to hit their targets.